Pomer S, Brado M, Roeren T, Brkovic D, Wiesel M, Staehler G, Keilholz U
Abteilung für Urologic, Universitätsklinik Heidelberg.
Urologe A. 1996 Jul;35(4):310-4.
Interleukin 2 (IL2)-based immunotherapy is effective in a subgroup of patients with metastatic renal cancer, but cure from liver metastases is very rare and even the selection of patients to be treated is very much limited by the toxicity of IL2. To reduce this toxicity and to augment the efficacy of intrahepatic IL2 application, a protocol of combined rIL2 (3 mg/day) and Lipiodol (2-5 ml/day according to tumour size), via a catheter inserted percutaneously into the hepatic artery, was implemented. As an adverse reaction, moderate fever (WHO) grade I and II was noted. A partial remission was seen in one patient and stable disease in four patients over a period of 2-6 years (median 32.2 month). It seems that immuno-embolisation of otherwise intractable liver metastases of renal cancer is well tolerated and its efficacy may be augmented by optimisation of the therapeutic protocol.
基于白细胞介素2（IL2）的免疫疗法对部分转移性肾癌患者有效，但肝转移灶的治愈极为罕见，甚至因IL2的毒性，可供治疗的患者选择也非常有限。为降低这种毒性并增强肝内应用IL2的疗效，实施了一项联合方案，即通过经皮插入肝动脉的导管，给予重组IL2（3毫克/天）和碘油（根据肿瘤大小，2 - 5毫升/天）。作为不良反应，观察到有中度发热（世界卫生组织分级为I级和II级）。在2至6年（中位时间32.2个月）期间，1例患者出现部分缓解，4例患者病情稳定。看来，免疫栓塞对原本难以治疗的肾癌肝转移灶耐受性良好，通过优化治疗方案，其疗效可能会增强。
